All In Biotech

Drug Trial Radar · NCT04585815

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

34

Actual

Start

Nov 10, 2020

Primary completion

May 17, 2023

Study completion Oct 29, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Sasanlimab Prefilled syringeDrug

    prefilled syringe

  • EncorafenibDrug

    capsules

  • BinimetinibDrug

    tablets

  • SasanlimabDrug

    solution supplied in vials

  • AxitinibDrug

    tablets

  • SEA-TGTDrug

    solution in vials

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)Time frame: Day 1 up to Day 28 of Cycle 1
  2. Phase 2 of Sub-Study A: Durable Objective Response Rate (ORR)Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
  3. Phase 1b of Sub-Study B: Percentage of Participants With DLTTime frame: Day 1 up to Day 21 of Cycle 1
  4. Phase 2 Sub-Study B: Objective Response RateTime frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)

Locations

55 sites in 4 countries. Site status is shown where the registry gives one.

  • City of Hope Investigational Drug Services (IDS)

    Duarte, California

  • City of Hope

    Duarte, California

  • UCSD Medical Center - Encinitas

    Encinitas, California

  • California Cancer Associates for Research and Excellence, Inc (cCARE)

    Fresno, California

  • The Oncology Institute of Hope and Innovation

    Glendale, California

  • Koman Family Outpatient Pavilion

    La Jolla, California

  • Sulpizio Cardiovascular Center at UC San Diego Health

    La Jolla, California

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California

  • UC San Diego Moores Cancer Center - Investigational Drug Services

    La Jolla, California

  • UCSD Perlman Medical Offices

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • The Oncology Institute of Hope and Innovation

    Long Beach, California

  • The Oncology Institute of Hope and Innovation

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • The Oncology Institute of Hope and Innovation

    Santa Ana, California

  • UCSD Medical Center - Vista

    Vista, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • AdventHealth Celebration Infusion Center

    Celebration, Florida

  • AdventHealth Medical Group Oncology Research at Celebration

    Celebration, Florida

  • Advent Health Orlando - Investigational Drug Services

    Orlando, Florida

  • AdventHealth Orlando Infusion Center

    Orlando, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Henry Ford Medical Center - Fairlane

    Dearborn, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Henry Ford Medical Center - Columbus

    Novi, Michigan

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Mount Sinai Hospital Pharmacy

    New York, New York

  • Tennessee Oncology PLLC

    Dickson, Tennessee

  • Tennessee Oncology PLLC

    Franklin, Tennessee

  • Tennessee Oncology PLLC

    Gallatin, Tennessee

  • Tennessee Oncology PLLC

    Hendersonville, Tennessee

  • Tennessee Oncology PLLC

    Hermitage, Tennessee

  • Tennessee Oncology PLLC

    Lebanon, Tennessee

  • Tennessee Oncology PLLC

    Murfreesboro, Tennessee

  • Sarah Cannon Research Institute - Pharmacy

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.